Ameritas Investment Partners, Inc. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 90 filers reported holding DENALI THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.1%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$242,155
-15.9%
11,738
+20.3%
0.01%
-9.1%
Q2 2023$287,900
+43.5%
9,756
+12.0%
0.01%
+37.5%
Q1 2023$200,655
-22.4%
8,7090.0%0.01%
-20.0%
Q4 2022$258,657
+13.0%
8,709
+16.6%
0.01%0.0%
Q3 2022$229,000
+4.6%
7,4690.0%0.01%
+11.1%
Q2 2022$219,000
-4.8%
7,469
+4.7%
0.01%
+12.5%
Q1 2022$230,000
-27.7%
7,1340.0%0.01%
-27.3%
Q4 2021$318,000
-11.7%
7,1340.0%0.01%
-15.4%
Q3 2021$360,000
-35.7%
7,1340.0%0.01%
-35.0%
Q2 2021$560,000
+91.8%
7,134
+39.5%
0.02%
+81.8%
Q1 2021$292,000
-33.8%
5,115
-2.9%
0.01%
-45.0%
Q4 2020$441,000
+121.6%
5,268
-5.2%
0.02%
+122.2%
Q3 2020$199,000
+48.5%
5,5550.0%0.01%
+50.0%
Q2 2020$134,000
+83.6%
5,555
+32.5%
0.01%
+50.0%
Q1 2020$73,0000.0%4,1930.0%0.00%
+33.3%
Q4 2019$73,000
+28.1%
4,193
+13.2%
0.00%0.0%
Q3 2019$57,000
-26.0%
3,7050.0%0.00%
-25.0%
Q2 2019$77,000
-10.5%
3,7050.0%0.00%0.0%
Q1 2019$86,000
+11.7%
3,7050.0%0.00%0.0%
Q4 2018$77,000
-4.9%
3,7050.0%0.00%0.0%
Q3 2018$81,000
+285.7%
3,705
+172.0%
0.00%
+300.0%
Q2 2018$21,000
-22.2%
1,3620.0%0.00%0.0%
Q1 2018$27,0001,3620.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q4 2018
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders